Tweet
BMC Infect Dis
. 2021 Feb 15;21(1):175.
doi: 10.1186/s12879-021-05848-8.
Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective
Hee-Sung Kim # 1 , Minseok Kang # 2 , Gilwon Kang 3 4
Affiliations
- PMID: 33588797
- DOI: 10.1186/s12879-021-05848-8
Abstract
Background: While hypertension is the most common comorbid condition in patients with coronavirus disease 2019 (COVID-19) in Korea, there is a lack of studies investigating risk factors in COVID-19 patients with hypertension in Korea. In this study, we aimed to examine the effects risk factors in hypertensive Korean COVID-19 patients.
Methods: We selected patients from the database of the project #OpenData4Covid19. This information was linked to their 3-year historical healthcare data. The severity of the disease was classified into five levels. We also clustered the levels into two grades.
Results: The risk factors associated with COVID-19 severity were old age, diabetes mellitus, cerebrovascular disease, chronic obstructive pulmonary disease (COPD), malignancy, and renal replacement therapy. The use of angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) both before and after a diagnosis of COVID-19 were not associated with COVID-19 severity. A multivariate analysis revealed that old age, male sex, diabetes mellitus, and renal replacement therapy were risk factors for severe COVID-19.
Conclusion: The results suggest that in hypertensive patients with COVID-19, older age, male sex, a diagnosis of diabetes mellitus, and renal replacement therapy were risk factors for a severe clinical course. In addition, the use of ARBs and ACEIs before or after COVID-19 infection did not affect a patient's risk of contracting COVID-19 nor did it contribute to a worse prognosis for the disease. These results highlighted that precautions should be considered for hypertensive patients with those risk factors and do not support discontinuation of ARBs and ACEIs during COVID-19 pandemic.
Keywords: Angiotensin converting enzyme inhibitor (ACEI); Angiotensin receptor blocker (ARB); COVID-19; Hypertension.